Patients decline buprenorphine from the emergency department CTN:0107 add on

患者拒绝从急诊科使用丁丙诺啡 CTN:0107 添加

• 批准号: 10666250
• 负责人: KATHLEEN T. BRADY
• 金额: $ 27.58万
• 依托单位: MEDICAL UNIVERSITY OF SOUTH CAROLINA
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-01 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10666250
• 关键词: Accident and Emergency department; Address; Buprenorphine; Consolidated Framework for Implementation Research; Country; Data; Dimensions; Emergency Department patient; Emergency Medicine; Evidence based treatment; Foundations; Funding; Harm Reduction; Individual; Instruction; Intervention; Interview; Knowledge; Length; Life; Medical; Minority; Modification; Opioid; Overdose; Overdose reduction; Pathway interactions; Patients; Pharmaceutical Preparations; Placebos; Principal Investigator; Provider; Public Health; Quality of Care; Recovery; Research; Research Design; Savings; Science; Social Functioning; South Carolina; Structure; Survey Methodology; Time; United States Dept. of Health and Human Services; acute care; addiction; buprenorphine treatment; comparative effectiveness study; craving; implementation science; improved; mortality; opioid epidemic; opioid use; opioid use disorder; patient engagement; patient-level barriers; peer; programs; therapy design; therapy development; uptake; user centered design; Accident and Emergency department; Address; Buprenorphine; Consolidated Framework for Implementation Research; Country; Data; Dimensions; Emergency Department patient; Emergency Medicine; Evidence based treatment; Foundations; Funding; Harm Reduction; Individual; Instruction; Intervention; Interview; Knowledge; Length; Life; Medical; Minority; Modification; Opioid; Overdose; Overdose reduction; Pathway interactions; Patients; Pharmaceutical Preparations; Placebos; Principal Investigator; Provider; Public Health; Quality of Care; Recovery; Research; Research Design; Savings; Science; Social Functioning; South Carolina; Structure; Survey Methodology; Time; United States Dept. of Health and Human Services; acute care; addiction; buprenorphine treatment; comparative effectiveness study; craving; implementation science; improved; mortality; opioid epidemic; opioid use; opioid use disorder; patient engagement; patient-level barriers; peer; programs; therapy design; therapy development; uptake; user centered design

Program Director/Principal Investigator (Last, First, Middle): Brady, Kathleen T PROJECT SUMMARY (See instructions): Why do patients decline buprenorphine from the emergency department?: Add-on study to CTN-0107 Emergency department-initiated buprenorphine (EDIB) successfully doubles retention in treatment at 30 days when compared to referral alone. Additionally, there are significant benefits to treatment with buprenorphine and other medications for opioid use disorder (MOUD) including significant reductions in overdose and all-cause mortality, better retention compared to placebo or no medication increased length of time in recovery, decreased opioid use, decreased craving, and improved social functioning. Emergency departments (EDs) are well-suited to engage patients in buprenorphine treatment, resulting in significantly improved ED quality of care and increased access to this life-saving treatment. Unfortunately, only a minority of patients eligible and offered EDIB receive it. The specific objective of this proposal is to systematically evaluate reasons why EDIB-eligible patients with OUD decline EDIB. This study will be a qualitative study utilizing semi-structured interviews with ED medical providers, ED staff, and patients who are deemed eligible for EDIB to evaluate provider/staff-level and patient-level barriers and facilitators to EDIB acceptance among eligible patients. This knowledge is imperative to public health efforts addressing the opioid epidemic, as results can be used to improve harm reduction interventions by addressing critical gaps for ED patients with OUD. This proposal would be the first to examine why a minority of patients eligible for EDIB accept it when it is available and recommended. This study will provide an important initial step in better understanding reasons for declining EDIB and informing intervention design and implementation to increase EDIB uptake. This study can be completed rapidly and has potential to positively impact the thousands of patients with OUD seen in EDs across the country. Our team of experts in addiction science, survey methods, qualitative data, implementation science and emergency medicine are uniquely qualified to carry out this proposal. RELEVANCE (See instructions): The proposed research will provide the foundation to address systematic problems with ED-initiated buprenorphine programs, which will in turn improve patient engagement in evidenced-based treatments.

计划主任/首席研究员（最后，第一，中间）：布雷迪，凯瑟琳T 项目摘要（请参阅说明）： 为什么患者会从紧急情况下拒绝丁丙诺啡 部门？：CTN-0107的附加研究 急诊室发起的丁丙诺啡（EDIB）成功地将保留率加倍 与单独推荐相比，30天。此外，对治疗有重大好处 丁丙诺啡和其他用于阿片类药物使用障碍（MOUD）的药物，包括大幅减少 与安慰剂相比，过量服用和全因死亡率，更好的保留率或没有药物增加的长度 恢复时间，阿片类药物使用的减少，渴望减少和社交功能的改善。紧急情况 部门（EDS）非常适合使患者接受丁丙诺啡治疗，从而显着 改善了ED护理质量并增加了获得这种救生治疗的机会。不幸的是，只有一个 符合条件并提供EDIB的少数患者会接受。 该提案的具体目的是系统地评估符合EDIB资格患者的原因 随着Oud的下降Edib。这项研究将是一项使用半结构化访谈的定性研究 被认为有资格获得EDIB的医疗提供者，ED员工和患者评估提供商/员工级别 以及符合条件的患者接受EDIB接受的患者级障碍和促进者。这些知识是 对于解决阿片类药物流行的公共卫生努力势在必行，结果可以用来改善伤害 减少干预措施，通过解决ED患者的关键差距来减少干预措施。 该提案将是第一个研究为什么有资格获得EDIB的少数患者接受的建议 可用并推荐。这项研究将为更好地理解提供重要的第一步 降低EDIB并告知干预设计和实施以增加EDIB吸收的原因。 这项研究可以迅速完成，并有可能对成千上万的患者产生积极影响 Oud在全国各地的ED中看到。我们成瘾科学专家团队，调查方法， 定性数据，实施科学和急诊医学具有独特的资格 提议。 相关性（请参阅说明）： 拟议的研究将为解决系统问题的系统问题提供基础 丁丙诺啡计划将改善患者参与基于历史的治疗方法。